Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX [PDF]
, 2018 Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with lack of predictive biomarkers. We conducted a study to assess DNA damage repair (DDR) gene mutations as a predictive biomarker in PDAC patients treated with FOLFIRINOX ...
Gbolahan, Olumide +8 more
core +1 more source
Scientific Reports, 2021 Treatment outcomes between FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) and GNP (gemcitabine with albumin-bound paclitaxel) as first-line chemotherapy regimens for metastatic pancreatic cancer (PC) were assessed according to ...
Yoon Suk Lee +4 more
doaj +1 more source
Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients
healthbook TIMES. Oncology Hematology, 2021 Despite oncological advances over the past years, survival outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain poor. For most PDAC patients, the disease is often asymptomatic at early phases and is therefore typically diagnosed at ...
Sara De Dosso +7 more
doaj +1 more source
Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. [PDF]
, 2018 BackgroundContinuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer.
Bedford, Rudolph +7 more
core +1 more source
Human Vaccines & Immunotherapeutics, 2021 The prognosis of patients with advanced pancreatic cancer is poor despite the recent introduction of immune checkpoint inhibitors. Therefore, the development of new therapeutic approaches is urgently required.
Shuichi Ota +3 more
doaj +1 more source
Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer: A Promising Approach. [PDF]
, 2018 Locally advanced pancreatic cancer (LAPC) is characterized by poor prognosis and low response durability with standard-of-care chemotherapy or chemoradiotherapy treatment.
Cao, Minsong +6 more
core +1 more source
Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience. [PDF]
, 2015 The objectives of this study were to evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NAB-P/GEM) regimen in an unselected population of patients with advanced inoperable or metastatic pancreatic cancer (PC), and to identify the prognostic ...
Basso, Smm +5 more
core +2 more sources
Gut and Liver, 2021 Background/Aims: There has been growing evidence on the utility of neoadjuvant FOLFIRINOX in borderline resectable (BR) or locally advanced (LA) pancreatic cancer.
Young Hoon Choi +9 more
doaj +1 more source
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer [PDF]
, 2013 AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer.
Bria, E. +9 more
core +1 more source
Predicting a response to FOLFIRINOX in pancreatic cancer [PDF]
JNCI Journal of the National Cancer Institute, 2015 Cancer of the pancreas is highly lethal and it is the fourth leading cause of cancer death in the United States (1). The majority of patients with pancreatic cancer have metastatic disease at the time of diagnosis, and the few patients who present with localized disease often develop metastases within two years of their surgery.
Ryan D, Nipp, David P, Ryan
openaire +2 more sources